Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/21/2025: EXEL (3-star) is a STRONG-BUY. BUY since 3 days. Profits (-0.33%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 46.84% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/21/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.40B USD | Price to earnings Ratio 23.5 | 1Y Target Price 35.61 |
Price to earnings Ratio 23.5 | 1Y Target Price 35.61 | ||
Volume (30-day avg) 2246124 | Beta 0.51 | 52 Weeks Range 20.02 - 37.59 | Updated Date 01/21/2025 |
52 Weeks Range 20.02 - 37.59 | Updated Date 01/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.55 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.43% | Operating Margin (TTM) 34.81% |
Management Effectiveness
Return on Assets (TTM) 12.81% | Return on Equity (TTM) 20.2% |
Valuation
Trailing PE 23.5 | Forward PE 21.05 | Enterprise Value 9343244524 | Price to Sales(TTM) 5 |
Enterprise Value 9343244524 | Price to Sales(TTM) 5 | ||
Enterprise Value to Revenue 4.49 | Enterprise Value to EBITDA 14.69 | Shares Outstanding 285579008 | Shares Floating 238455626 |
Shares Outstanding 285579008 | Shares Floating 238455626 | ||
Percent Insiders 1.78 | Percent Institutions 89.05 |
AI Summary
Exelixis Inc.: A Comprehensive Overview
Company Profile
History and Background: Founded in 1994, Exelixis Inc. is a biopharmaceutical company dedicated to discovering and developing innovative therapies for cancer patients. Initially focused on small molecule drugs, it shifted its focus to targeted therapies in 2002, leading to the development of its first FDA-approved drug, Cabometyx.
Core Business Areas: Exelixis primarily focuses on two areas:
- Developing and commercializing its own oncology products: This includes Cabometyx, Cometriq, and Cotellic, all approved for various types of cancer.
- Research and development of novel cancer therapies: This involves identifying and developing new small molecule and biologic therapies targeting various cancer pathways.
Leadership and Corporate Structure: The company is led by CEO Michael Morrissey, PhD, and a team of experienced executives with expertise in drug development, commercialization, and finance.
Top Products and Market Share
Top Products:
- Cabometyx: A tyrosine kinase inhibitor used to treat renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. It is Exelixis' flagship product, generating most of the company's revenue.
- Cometriq: A kinase inhibitor used in combination with other drugs to treat advanced thyroid cancer.
- Cotellic: A small molecule inhibitor targeting the MET receptor, used to treat advanced non-small cell lung cancer.
Market Share: Exelixis holds a significant market share in the targeted therapy space for some cancer types. For instance, Cabometyx holds a dominant position in the second-line treatment of advanced renal cell carcinoma. However, the company faces competition from other players in the oncology market.
Product Performance and Market Reception: Cabometyx has been well-received by the market, with strong sales growth and positive clinical trial results. Cometriq and Cotellic have also shown promising potential, but their market penetration is lower compared to Cabometyx.
Total Addressable Market
The global market for oncology drugs is vast and expected to reach $309.9 billion by 2028. Exelixis primarily targets specific segments within this market, focusing on therapies for kidney, liver, and lung cancers.
Financial Performance
Revenue and Profitability: Exelixis has experienced consistent revenue growth in recent years, driven by the success of Cabometyx. However, the company has yet to achieve profitability due to ongoing research and development investments.
Financial Health: The company has a strong cash position and minimal debt, indicating a healthy financial profile.
Shareholder Returns: Exelixis has delivered significant shareholder returns in recent years, with its stock price appreciating significantly.
Growth Trajectory
Exelixis has a strong growth trajectory driven by the continued success of Cabometyx and the potential of its pipeline candidates. The company expects continued revenue growth and potential profitability in the coming years.
Market Dynamics
The oncology market is experiencing constant innovation and competition. Exelixis needs to adapt to these changes and maintain its competitive edge through R&D efforts and strategic partnerships.
Competitors
Key competitors:
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Pfizer (PFE)
- Roche (RHHBY)
- Bayer (BAYRY)
Competitive Advantages: Exelixis has a strong product portfolio, particularly in the treatment of kidney cancer. The company also has a promising pipeline of potential new therapies.
Competitive Disadvantages: Exelixis is a smaller company compared to its competitors, potentially limiting its resources and market reach.
Potential Challenges and Opportunities
Challenges: Exelixis faces challenges maintaining its market share and navigating the competitive landscape. Additionally, the company needs to successfully develop and commercialize its pipeline candidates to achieve long-term growth.
Opportunities: Exelixis has opportunities to expand its market reach through new product launches and strategic partnerships. The company can also leverage its expertise in targeted therapies to develop new treatments for other types of cancer.
Recent Acquisitions
Exelixis hasn't made any significant acquisitions in the last three years.
AI-Based Fundamental Rating
Rating: 7/10
Justification: Exelixis has a strong product portfolio, a promising pipeline, and solid financials. However, the company faces challenges in the competitive oncology market and needs to successfully develop its pipeline candidates to achieve long-term growth.
Sources and Disclaimers
Sources:
- Exelixis Inc. website: https://investor.exelixis.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports: https://www.statista.com/
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1310 | Website https://www.exelixis.com |
Full time employees 1310 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.